A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-08 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
===== Transgenic plants ===== Transgenic crops have been made to express dsRNA, carefully chosen to silence crucial genes in target pests. These dsRNAs are designed to affect only insects that express specific gene sequences. As a proof of principle, in 2009 a study showed RNAs that could kill any one of four fruit fly species while not harming the other three.
As the head group forms such compact bicycle structure, the head group area is quite small relative to the big tail region consisting of 4 acyl chains. Based on this special structure, the fluorescent mitochondrial indicator, nonyl acridine orange (NAO) was introduced in 1982, and was later found to target mitochondria by binding to CL. NAO has a very large head and small tail structure which can compensate with cardiolipin's small head and large tail structure, and arrange in a highly ordered way. Several studies were published utilizing NAO both as a quantitative mitochondrial indicator and an indicator of CL content in mitochondria. However, NAO is influenced by membrane potential and/or the spatial arrangement of CL, so it's not proper to use NAO for CL or mitochondria quantitative studies of intact respiring mitochondria. But NAO still represents a simple method of assessing CL content.
From about 1989 to 2018, Ontario has reported a deficit almost every year; the province's net debt increased to approximately $311.6 billion (by October 2018); and Ontario's net debt‐to‐GDP ratio grew from 13.4% to about 40.5% in 2018–19. According to an April 11, 2018 Royal Bank of Canada (RBC) report, which was based on figures provided by the Ford government, the revised estimate of Ontario's deficit was $11.7 billion in 2018–2019 and it was projected to decrease by $1.4 billion in 2019–2020 mainly because of "the removal of the $1 billion contingency reserve." At that time, it was projected that the deficit would be "completely eliminated in 2023–2024 with a small surplus of $0.3 billion." By October 2019, the Financial Accountability Officer, Weltman, said that the FAO had been in error when they—and the Ford government—had projected a $11.7-billion deficit that was reported in the spring 2019 budget. By June 2018, Ontario had "Canada's second-highest public debt per person and a growing budget deficit", according to The Economist. In October 2018, the Ontario Finance Department reported that Ontario's public debt per person, at $23,014, had surpassed that of Quebec at $21,606 in the fiscal year 2017–2018. Newfoundland and Labrador's public debt per capita, at $27,761, was the highest in Canada. By 2019, the Ontario Chamber of Commerce reported that Ontario's debt was over $348 billion—representing about 41% of provincial GDP of almost $850 billion. Ontario's GDP is much larger than any of the other provinces and is almost half of Canada's GDP.
== History == Paniz-Mondolfi was born in Caracas, Venezuela in 1976. His mother is a pediatrician and his father an architect. His grandfather, Edgardo Mondolfi Otero, a biologist and zoologist. Two of his uncles were physicians with special ambitions in the field of sciences and research. His childhood was shared between Caracas and Kenya. Paniz-Mondolfi has a master's degree in parasitology and tropical diseases; he did international fellowships in microbiology, molecular genetics, and skin disease. He also did a second medical residency in the United States in pathology. He isolated and described a new species of parasite that had infected a NY resident, and a new mycobacterium that sickened two people in Connecticut. He earned an MD and PhD and studied under Jacinto Convit the leprosy researcher. He was a pathologist at the IDB Biomedical Research Institute in Barquisimeto, Venezuela until 2019 when he fled to the United States. He is the founder of the Venezuelan Science Incubator, an independent health research organization. Paniz-Mondolfi is assistant professor of pathology, molecular and cell-based medicine at the Mount Sinai Icahn School of Medicine. He is also affiliated with the Yale Cancer Center. In 2020 he focused his research on the COVID-19 pandemic and the effects the virus had on minority children. His research findings have been published in several medical journals including: the European Society of Clinical Microbiology and Infectious Diseases, The American Association for the Advancement of Science, and The Lancet.
Sources: en.wikipedia.org
Lineage, Inc. (formerly Lineage Logistics) is the world's largest temperature-controlled warehouse real estate investment trust (REIT), owned by Bay Grove, LLC. Entering international markets in 2017, Lineage grew into the world's largest refrigerated warehousing company with a capacity exceeding 3 billion cubic feet and acquiring more than 100 companies through the end of 2023. Lineage operates over 450 facilities across 18 countries, with approximately 26,000 team members globally in North America, Europe, and Asia Pacific.
Regarding the positive roles of film in education, a case study analyzing students in medical fields found that the appropriate use of movies can provide helpful ideas in applying practical skills related to the medical fields, such as medical ethics, doctor-patient relationships, and mental illness. Celebrity Disclosures Celebrities' influences and their own personal experiences with mental illness can help in decreasing the stereotypes and stigma surrounding mental illness. Stars, including Lady Gaga, Serena Williams, Adele, and Dwayne Johnson, have recently disclosed their mental health journeys. Celebrities disclosing their personal experiences can help inform the public about symptoms and services regarding mental health, allowing mental health struggles to feel more normal and accepted. According to the social learning theory, people often adopt behaviors by observing others, especially celebrities, and seeing the outcomes of their actions. When a celebrity reveals their mental health struggles and remains successful and respected, it can help reduce the fear of facing negative consequences for sharing personal experiences.
== Urine tests == Urine bilirubin may also be clinically significant. Bilirubin is not normally detectable in the urine of healthy people. If the blood level of conjugated bilirubin becomes elevated, e.g. due to liver disease, excess conjugated bilirubin is excreted in the urine, indicating a pathological process. Unconjugated bilirubin is not water-soluble and so is not excreted in the urine. Testing urine for both bilirubin and urobilinogen can help differentiate obstructive liver disease from other causes of jaundice. As with billirubin, under normal circumstances, only a very small amount of urobilinogen is excreted in the urine. If the liver's function is impaired or when biliary drainage is blocked, some of the conjugated bilirubin leaks out of the hepatocytes and appears in the urine, turning it dark amber. However, in disorders involving hemolytic anemia, an increased number of red blood cells are broken down, causing an increase in the amount of unconjugated bilirubin in the blood. Because the unconjugated bilirubin is not water-soluble, one will not see an increase in bilirubin in the urine. Because there is no problem with the liver or bile systems, this excess unconjugated bilirubin will go through all of the normal processing mechanisms that occur (e.g., conjugation, excretion in bile, metabolism to urobilinogen, reabsorption) and will show up as an increase of urobilinogen in the urine. This difference between increased urine bilirubin and increased urine urobilinogen helps to distinguish between various disorders in those systems.
Sources: en.wikipedia.org
=== Bethlem myopathy 2 === (Collagen XII gene) See Bethlem myopathy 2 Clinical synopsis on OMIM: 616471 In Bethlem myopathy 2, there is phenotypic variability. In one family, the only notable finding on T1-weighted MR images (used to detect fatty infiltration) was atrophy of the rectus femoris muscles of the thigh, with the degree of atrophy matching the severity of the disease, but no fatty infiltration. In another family, only the more severely affected older patient showed significant abnormality, by having symmetrical fatty atrophy of the femoral quadriceps of the thigh, the adductor and medial gastrocnemius muscles of the calf; as well as asymmetrical fatty atrophy of the adductor longus of the thigh. No muscle hypertrophy was reported and the muscles of the patients without fatty atrophy appeared normal. Bethlem myopathy 2 also differs by including the possibility of scapula winging, pectus excavatum, stooped posture, kyphosis (hunchback), micrognathia, retrognathia, and a high-arched palate. Childhood muscle weakness improves in teen years, but muscle weakness returns by the third decade of life.
== Medical uses == Allogeneic cultured keratinocytes and fibroblasts in bovine collagen is indicated for topical (non-submerged) application to a surgically created vascular wound bed in the treatment of mucogingival conditions in adults.
=== Neurological disease === FcRn is expressed at the blood–brain barrier (BBB), where it helps regulate the movement of IgG antibodies between the brain and peripheral circulation. Although IgG can enter the brain via passive diffusion in small amounts, FcRn primarily functions to transport IgG out of the CNS, contributing to immune surveillance and IgG clearance from the brain parenchyma. This efflux activity has implications for neuroinflammatory and neurodegenerative conditions, where pathogenic IgG accumulation in the CNS may be exacerbated by impaired FcRn function. Additionally, FcRn is being explored as a route for antibody-based drug delivery to the brain, using engineered Fc domains to engage FcRn-mediated transcytosis across the BBB.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.